Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | $30.00 | Buy | Citigroup |
| 1/22/2026 | Neutral → Overweight | Piper Sandler | |
| 12/9/2025 | $30.00 | Overweight | Barclays |
| 11/21/2025 | $27.00 | Overweight | KeyBanc Capital Markets |
| 11/19/2025 | $25.00 | Hold → Buy | Argus |
| 10/7/2025 | $24.00 | Neutral → Overweight | Analyst |
| 7/17/2025 | $18.00 | Market Perform → Outperform | Leerink Partners |
| 6/26/2025 | Mkt Perform → Outperform | William Blair |
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00
Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight
Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today reaffirms its commitment to providing veterinarians, livestock produ
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.Stable Expectations for Pet Owner Spend:
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics todayBefrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their jo
SD - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre
National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC
MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)